Patient, Manufacturer, and Other Stakeholder Engagement

ICER is committed to a transparent public engagement process to ensure that all stakeholders have the opportunity to provide input to our reports.

More detailed information regarding ICER’s public engagement process may be found below and in these documents:

ICER Patient Participation Guide
ICER Guide to Open Input for Patients
ICER Manufacturer Engagement Guide (updated February 1, 2017)

These guides are open to public comment until April 3, 2017. Suggestions for improvement can be emailed to publiccomments@icer-review.org. 

Our interactive, transparent process starts with Topic Selection.

Once a topic is announced, there are four formal opportunities, outlined below, for patients, manufacturers, and other stakeholders to provide written and/or oral feedback. Written comments from the public are invited at three times during the report preparation process, and there is an additional opportunity for oral comment at the public meeting.

Please note that all submitted comments may be made public.

Public comments allow ICER to address the concerns of patients, clinicians, policymakers, manufacturers, and other health care decision makers and ensure that the report has the broadest possible relevancy. 

Please note that the details below reflect our updated process.  Not all in-process reports will follow this timeline.  Links to all of the current timelines are available on the relevant meeting page: multiple sclerosis and rheumatoid arthritis.

1) Open Input Period

Once a topic has been announced, ICER will accept comments on the upcoming review from patients and other stakeholders as part of an “Open Input” period. During this period, which extends for about three weeks after the topic announcement , stakeholders are encouraged to submit commentary, citations, and guidance relevant to the topic of the upcoming review, especially for:

  • Important patient-relevant and patient-centered outcomes, especially those not adequately captured in the clinical trial data
  • Other benefits and disadvantages
  • Key research needs
  • Contextual considerations
  • Any other input deemed relevant and critical to a comprehensive understanding of the evidence base

Our patient guide to open input may be helpful to patients and patient groups providing input.

There are no page limits to Open Input submissions. The Open Input period is intended to function as a complement to the subsequent public comment period on a draft scoping document. The information gathered during the Open Input period is used to inform the development of the draft scoping document and the report.

All submissions can be emailed to publiccomments@icer-review.org and must be received by the deadline specified in the relevant topic announcement.

2) Draft Scoping Document

The draft scoping document details the proposed topic, including the population, interventions, comparators, outcomes, timeframe, and setting(s) of care. The Draft Scoping Document will be posted for public comment for three weeks, during which anyone can comment on the proposed scope to help ensure that the report and meeting are most relevant to the broadest possible audiences.  To submit a public comment on the draft scoping document, members of the public must submit their comments by email to publiccomments@icer-review.org within three weeks of posting. ICER staff may follow up for further clarification and potential consultation. All comments must be submitted following the below formatting specifications: 

  • Times New Roman, 12-point font size
  • Three pages maximum (excluding references)
  • Word document (no PDFs)
  • Electronic copy only

Written comments will be posted publicly to the ICER website with the Draft Evidence Report.

3) Draft Evidence Report and Draft Voting Questions

Both documents will be posted to the relevant program’s webpage with an announcement (approximately seven weeks prior to the meeting date), and the public comment period will be open for four weeks. Anyone may comment on the Draft Evidence Report, and ICER will consider incorporating the feedback in an updated Evidence Report that will be posted before the in-person meeting. Written comments will be posted publicly to the ICER website with the Evidence report and will be distributed to members of the relevant voting body prior to the public meeting. Members of the public wishing to submit a written public comment on the Draft Evidence Report or voting questions must do so within the four week posting period. Comments must be emailed as an attachment to publiccomments@icer-review.org and must meet the following style requirements:

  • Times New Roman, 12-point font size
  • Five pages maximum (excluding references)
  • Word document (no PDFs)
  • Electronic copy only

After all public comments have been received, ICER staff will prepare revised versions of the draft report and voting questions. The process of addressing public comments and revising the draft report and voting questions can take up to two weeks. A revised Evidence Report and voting questions are then posted to the ICER website and distributed to the voting panel for review and meeting preparation.

4) Oral Comments at the public meeting

Each public meeting includes time for oral public comments. Those wishing to speak at the meeting must contact ICER via email (publiccomments@icer-review.org) and provide the name, title, and organization of the speaker. The period to submit a request to speak begins when the Draft Evidence Report is posted and ends when the written public comment period on the Draft Evidence Report closes. For specific dates, see the report timeline on the relevant meeting page.

Each manufacturer involved in the review is offered time to speak during the oral public comment period.  For other public comments, since there may be more requests than can be accommodated during the meeting, and to help provide the opportunity for a broad range of stakeholder perspectives to be heard, public comment slots will only be able to confirmed after the deadline for requests has passed. Priority for these additional public comment slots will be given to patients with the condition under study and subject-matter experts from the patient advocacy, clinical, and research communities. All potential speakers are required to complete a conflict of interest form. All disclosures will be made public at the meeting. Comments at the meeting will be limited to five minutes.

More detailed information regarding ICER’s public engagement process may be found in the documents below:

ICER Patient Participation Guide
ICER Manufacturer Engagement Guide (updated February 1, 2017)
ICER’s Guide to Open Input for Patients
These guides are open to public comment until April 3, 2017. Suggestions for improvement can be emailed to publiccomments@icer-review.org.